FDA’s Peter Stein And Lessons From Makena: There Are Limits To Regulatory Flexibility

Office of New Drug head said agency was willing to apply regulatory flexibility when it granted Makena its initial accelerated approval but says to give the drug the type of flexibility sponsor Covis wants now would set a ‘troubling’ precedent.